<?xml version="1.0" encoding="UTF-8"?>
<document id="29345289">
	<sentence id="s1" text="The use of recombinant human erythropoietin (Epo) has consistently been shown to reduce the need for blood transfusions and to increase hemoglobin levels in lung cancer patients with chemotherapy-induced anemia.">
		<entity id="s1.e1" charOffset="45-48"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s1.e2" charOffset="162-168"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="However, clinical and preclinical studies have prompted concerns that Epo and the presence of its receptor, EpoR, in tumor cells may be responsible for adverse effects and, eventually, death.">
		<entity id="s2.e1" charOffset="70-73"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s2.e2" charOffset="117-122"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="The question has been raised whether Epo promotes tumor growth and inhibits the death of cancer cells.">
		<entity id="s3.e1" charOffset="37-40"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s3.e2" charOffset="50-55"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e3" charOffset="89-95"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
	<sentence id="s4" text="Since the protein expression of both Epo and EpoR is induced by hypoxia, which is frequently present in lung cancer, the cells were treated with Epo under both normoxic and hypoxic conditions (1% O2).">
		<entity id="s4.e1" charOffset="37-40"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s4.e2" charOffset="109-115"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
	</sentence>
	<sentence id="s5" text="By using quantitative (real-time) PCR, western blot analysis, and immunocytochemical staining, three non-small cell lung cancer (NSCLC) cell lines (A427, A549 and NCI-H358) were analyzed for the expression of EpoR and its specific downstream signaling pathways [Janus kinase 2 (Jak2)-signal transducer and activator of transcription 5 (STAT5), phosphatidylinositol-3-kinase (PI3K)-Akt, mitogen-activated protein (MAP) kinase].">
		<entity id="s5.e1" charOffset="121-127"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s5.e2" charOffset="209-212"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s5.e3" charOffset="278-282"
			type="GENE" text="Jak2" ontology_id="3717"/>
		<entity id="s5.e4" charOffset="381-384"
			type="GENE" text="Akt" ontology_id="207"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="false"/>
		<pair id="s5.p2" e1="s5.e1"
		    e2="s5.e3" pgr="true"/>
		<pair id="s5.p3" e1="s5.e1"
		    e2="s5.e4" pgr="true"/>
	</sentence>
	<sentence id="s6" text="While Epo markedly enhanced the proliferation and reduced apoptosis of Epo-dependent UT-7/Epo leukemia cells, it did not affect tumor cell proliferation or the cisplatin-induced apoptosis of NSCLC cells.">
		<entity id="s6.e1" charOffset="6-9"
			type="GENE" text="Epo" ontology_id="8288"/>
		<entity id="s6.e2" charOffset="128-133"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s6.p1" e1="s6.e1"
		    e2="s6.e2" pgr="false"/>
	</sentence>
	<sentence id="s7" text="Thus, this in vitro study suggests that there are no tumor-promoting effects of Epo in the NSCLC cell lines studied, neither under normoxic nor under hypoxic conditions">
		<entity id="s7.e1" charOffset="53-58"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s7.e2" charOffset="80-83"
			type="GENE" text="Epo" ontology_id="8288"/>
		<pair id="s7.p1" e1="s7.e1"
		    e2="s7.e2" pgr="false"/>
	</sentence>
</document>
